KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Common Equity (2017 - 2025)

Bionano Genomics' Common Equity history spans 7 years, with the latest figure at $49.8 million for Q3 2025.

  • For Q3 2025, Common Equity rose 1.91% year-over-year to $49.8 million; the TTM value through Sep 2025 reached $49.8 million, up 1.91%, while the annual FY2024 figure was $35.4 million, 63.21% down from the prior year.
  • Common Equity for Q3 2025 was $49.8 million at Bionano Genomics, up from $45.4 million in the prior quarter.
  • Across five years, Common Equity topped out at $362.7 million in Q1 2021 and bottomed at $35.4 million in Q4 2024.
  • The 5-year median for Common Equity is $214.8 million (2023), against an average of $187.7 million.
  • The largest annual shift saw Common Equity skyrocketed 8709.49% in 2021 before it crashed 64.24% in 2024.
  • A 5-year view of Common Equity shows it stood at $337.1 million in 2021, then dropped by 26.02% to $249.4 million in 2022, then crashed by 61.44% to $96.2 million in 2023, then plummeted by 63.21% to $35.4 million in 2024, then skyrocketed by 40.77% to $49.8 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Common Equity are $49.8 million (Q3 2025), $45.4 million (Q2 2025), and $48.2 million (Q1 2025).